MESO
Closed
Mesoblast Ltd
12.12
+1.23 (+11.29%)
Last Update: 01 Jul 2025 23:00:00
Yesterday: 10.89
Day's Range: 11.72 - 12.5035
Send
sign up or login to leave a comment!
When Written:
3.34
Mesoblast Ltd is a biopharmaceutical company that focuses on developing regenerative medicine therapies using mesenchymal lineage adult stem cells. The company's lead product candidate, remestemcel-L, is being developed for various inflammatory conditions, including acute graft versus host disease (GVHD), chronic heart failure, and COVID-19-related acute respiratory distress syndrome. Mesoblast also has a pipeline of other product candidates in various stages of development for the treatment of various diseases, including degenerative disc disease, diabetic nephropathy, and rheumatoid arthritis. The company is headquartered in Melbourne, Australia, and has operations in the United States, Singapore, and Europe. Mesoblast was founded in 2004 and went public in 2004.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!








